公开(公告)号：US20120244069A1

公开(公告)日：2012-09-27

申请号：US13465181

申请日：2012-05-07

Applicant: Janine SCHUURMAN ,  Catharina Emanuele Gerarda HAVENITH ,  Paul PARREN ,  Jan G. J. VAN DE WINKEL ,  Denise Leah WILLIAMS ,  Jørgen PETERSEN ,  Ole BAADSGAARD

Inventor： Janine SCHUURMAN ,  Catharina Emanuele Gerarda HAVENITH ,  Paul PARREN ,  Jan G. J. VAN DE WINKEL ,  Denise Leah WILLIAMS ,  Jørgen PETERSEN ,  Ole BAADSGAARD

IPC: A61K39/395 ,  A61K51/10 ,  C07K16/28 ,  A61P19/02 ,  A61P3/10 ,  A61N5/06 ,  A61P21/04 ,  A61P1/00 ,  A61P1/04 ,  A61P11/06 ,  G01N33/577 ,  A61M37/00 ,  C07K17/00 ,  A61P25/00

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/062 ,  C07K16/4258 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/56966 ,  G01N33/57492 ,  G01N33/6854 ,  G01N33/6869 ,  G01N2333/70596 ,  G01N2333/715 ,  G01N2333/7155

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了结合并抑制人CD25的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人类转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物，产生人抗体的杂交瘤和转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20110099647A1

公开(公告)日：2011-04-28

申请号：US12886930

申请日：2010-09-21

Applicant: Michel DE WEERS ,  Yvo GRAUS ,  Judith OPRINS ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Martine VAN VUGT

Inventor： Michel DE WEERS ,  Yvo GRAUS ,  Judith OPRINS ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Martine VAN VUGT

IPC: A01K67/00 ,  A61K49/00 ,  A61K39/395 ,  G01N33/53 ,  C12N5/16 ,  C12N5/02 ,  C07K16/18 ,  C07H21/00 ,  A01H5/00 ,  A61P35/00 ,  A61P43/00

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K49/0004 ,  A61K2039/505 ,  C07K14/70596 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/566 ,  G01N2333/70596

Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与人CD38结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 还公开了包含人抗体的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20110091473A1

公开(公告)日：2011-04-21

申请号：US12739270

申请日：2008-10-22

Applicant: Jakub Golab ,  Magdalena Winiarska ,  Paul Parren ,  Wendy Mackus ,  Patrick Engelberts

Inventor： Jakub Golab ,  Magdalena Winiarska ,  Paul Parren ,  Wendy Mackus ,  Patrick Engelberts

IPC: A61K39/395 ,  A61P37/02 ,  A61P9/10

CPC classification number: C07K16/2887 ,  A61K39/39558 ,  A61K45/06 ,  C07K2317/732 ,  C07K2317/734 ,  A61K2300/00

Abstract: Antibody capable of mediating effector function which specifically binds to a multiple membrane spanning antigen or to an antigen which forms dimers or multimers (i) for use in combination with a cholesterol-increasing agent in the treatment of a disease or disorder associated with said antigen, wherein antibody-induced effector function has a beneficial effect on said disease or disorder or (ii) for use in the treatment of such disease or disorder, wherein the antibody is to be administered to a subject undergoing therapy with a cholesterol-lowering agent, such as a statin, and wherein the subject is withdrawn from treatment with the cholesterol-lowering agent prior to the administration of the antibody. Furthermore, a kit of parts comprising such antibody as well as a cholesterol-increasing agent.

Abstract translation: 能够介导效应子功能的抗体，其特异性结合跨越抗原的多重膜或形成二聚体或多聚体的抗原（i）与胆固醇增加剂组合用于治疗与所述抗原相关的疾病或病症， 其中抗体诱导的效应子功能对所述疾病或病症具有有益效果，或（ii）用于治疗这种疾病或病症，其中抗体将被施用于正在用降胆固醇药物治疗的受试者，例如 作为他汀类，并且其中所述受试者在施用所述抗体之前从所述胆固醇降低剂中撤出治疗。 此外，还包含一些包含这种抗体的部分试剂盒以及一种胆固醇增加剂。

公开(公告)号：US20100322939A1

公开(公告)日：2010-12-23

申请号：US12664258

申请日：2008-06-17

Applicant: Jens Overgaard

Inventor： Jens Overgaard

IPC: A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61K39/39558 ,  A61K41/0038 ,  A61K2039/545 ,  A61N5/10 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/565 ,  A61K2300/00

Abstract: The invention relates to a method for the treatment of an EGFR-associated tumor comprising administration, to an individual in need thereof, of an anti-EGFR antibody in combination with radiotherapy and a radiosensitising agent. In one embodiment, the treatment further comprises administration of a chemotherapeutic agent.

Abstract translation: 本发明涉及一种治疗EGFR相关肿瘤的方法，包括向有需要的个体施用抗EGFR抗体与放射治疗和放射增敏剂的组合。 在一个实施方案中，治疗还包括施用化学治疗剂。

公开(公告)号：US20100267934A1

公开(公告)日：2010-10-21

申请号：US12602439

申请日：2008-05-30

Applicant: Jan Van De Winkel ,  Tom Vink ,  Janine Schuurman ,  Paul Parren ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschote

Inventor： Jan Van De Winkel ,  Tom Vink ,  Janine Schuurman ,  Paul Parren ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschote

IPC: C07K16/24 ,  C07K16/18 ,  C12P21/08

CPC classification number: C07K16/2887 ,  A61K47/6803 ,  A61K47/6813 ,  A61K47/6835 ,  A61K47/6839 ,  A61K47/6845 ,  A61K47/6849 ,  A61K51/10 ,  A61K51/1006 ,  A61K51/1021 ,  A61K51/1027 ,  A61K51/103 ,  A61K51/1039 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/16 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/94

Abstract: The present invention relates to stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

Abstract translation: 本发明涉及稳定的IgG4抗体，涉及产生此类抗体的方法以及此类抗体作为药物的用途。 在一个主要方面，本发明涉及一种稳定的IgG4抗体，其包含重链和轻链，其中所述重链包含具有在位置（409）处的Arg残基取代的人IgG4恒定区， 位置（405）或位置（370）处的Lys残基。

公开(公告)号：US20100008929A1

公开(公告)日：2010-01-14

申请号：US12464057

申请日：2009-05-11

Applicant: Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Edward Halk ,  Arnout F. Gerritsen ,  Jorgen Petersen ,  Ole Baadsgaard

Inventor： Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Edward Halk ,  Arnout F. Gerritsen ,  Jorgen Petersen ,  Ole Baadsgaard

IPC: A61K39/395 ,  C07K16/00 ,  A61P35/00 ,  A61P19/02 ,  A61P3/10 ,  A61P25/28 ,  C12N5/08

CPC classification number: C07K16/2863 ,  A01K2217/05 ,  A01K2217/075 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56966

Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与人EGFR特异性结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20090317382A1

公开(公告)日：2009-12-24

申请号：US12096196

申请日：2006-12-15

Applicant: Mario Losen ,  Pilar Martinez-Martinez ,  Marc H. De Baets ,  Yvo Graus ,  Janine Schuurman ,  Paul Parren

Inventor： Mario Losen ,  Pilar Martinez-Martinez ,  Marc H. De Baets ,  Yvo Graus ,  Janine Schuurman ,  Paul Parren

IPC: A61K39/395 ,  C07K16/42 ,  A61P37/00

CPC classification number: C07K16/286 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/71

Abstract: The invention relates to the treatment of autoimmune diseases and disorders, in particular myasthenia gravis, by administration of effector-function-deficient antibodies, wherein said effector-function-deficient antibodies are capable of competing with one or more of the auto-antibodies involved in mediating the antibody-mediated auto-immune disease or disorder for binding to a target auto-antigen.

Abstract translation: 本发明涉及通过施用效应子功能缺陷型抗体治疗自身免疫性疾病和病症，特别是重症肌无力，其中所述效应子功能缺陷型抗体能够与参与的一种或多种自身抗体竞争 介导抗体介导的自身免疫疾病或病症以结合靶标自身抗原。

公开(公告)号：US07595378B2

公开(公告)日：2009-09-29

申请号：US10320094

申请日：2002-12-16

Applicant: Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Edward Halk ,  Arnout F. Gerritsen ,  Jørgen Petersen ,  Ole Baadsgaard

Inventor： Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Edward Halk ,  Arnout F. Gerritsen ,  Jørgen Petersen ,  Ole Baadsgaard

IPC: C12P21/08 ,  C07K16/00 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A01K2217/05 ,  A01K2217/075 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56966

Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与人EGFR特异性结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20090117584A1

公开(公告)日：2009-05-07

申请号：US11922990

申请日：2006-06-29

Applicant: Rene Toes ,  Thomas Huizinga ,  Miranda Molenaar ,  Paul Parren ,  Jan Van De Winkel

Inventor： Rene Toes ,  Thomas Huizinga ,  Miranda Molenaar ,  Paul Parren ,  Jan Van De Winkel

IPC: G01N33/53 ,  A01K67/00

CPC classification number: G01N33/5088

Abstract: Use of a non-human mammalian disease model, wherein the non-human mammal has been implanted with human synovial tissue or other human inflamed tissue containing anti-CCP (cyclic citrullinated peptide) antibody producing cells for (i) analyzing cellular processes in a disease associated with anti-CCP antibodies in such human synovial tissue or other human inflamed tissue, (ii) studying the role of anti-CCP antibodies in the induction and progression of a disease associated with anti-CCP antibodies, (iii) testing the efficacy of a therapeutic agent for the prevention or treatment of a disease associated with anti-CCP antibodies, and (iv) identifying a therapeutic agent useful for the prevention or treatment of a disease associated with anti-CCP antibodies. In one embodiment the non-human mammalian disease model is a mouse, such as a SCID mouse, and the disease associated with anti-CCP antibodies is arthritis, such as RA (rheumatoid arthritis).

Abstract translation: 使用非人哺乳动物疾病模型，其中所述非人哺乳动物已经植入人滑膜组织或其它含有抗CCP（环状瓜氨酸化肽）抗体产生细胞的人发炎组织，用于（i）分析疾病中的细胞过程 与所述人滑膜组织或其他人发炎组织中的抗CCP抗体相关，（ii）研究抗CCP抗体在与抗CCP抗体相关的疾病的诱导和进展中的作用，（iii）测试抗CCP抗体 用于预防或治疗与抗CCP抗体相关的疾病的治疗剂，和（iv）鉴定可用于预防或治疗与抗CCP抗体相关的疾病的治疗剂。 在一个实施方案中，非人哺乳动物疾病模型是小鼠，例如SCID小鼠，并且与抗CCP抗体相关的疾病是关节炎，例如RA（类风湿性关节炎）。

公开(公告)号：US07507408B2

公开(公告)日：2009-03-24

申请号：US10972296

申请日：2004-10-25

Applicant: Christian Reiter ,  Francois Habersetzer ,  Anne Fournillier ,  Christian Trepo ,  Claude Desgranges ,  Genevieve Inchauspe

Inventor： Christian Reiter ,  Francois Habersetzer ,  Anne Fournillier ,  Christian Trepo ,  Claude Desgranges ,  Genevieve Inchauspe

IPC: A61K39/29 ,  A61K39/42 ,  A61K39/12 ,  C12Q1/70 ,  G01N35/53

CPC classification number: G01N33/5767 ,  A61K2039/505 ,  C07K16/109 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/76

Abstract: Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.

Abstract translation: 描述了特异性识别HCV糖蛋白E2的构象依赖性表位的新型抗体，并且能够中和E2蛋白与敏感细胞的结合。 此外，提供了由上述抗体识别的抗原和表位以及编码所述抗体的多核苷酸。 还提供了包含所述多核苷酸的载体以及转化的宿主细胞及其在所述抗体的产生中的用途。 此外，提供药物和诊断组合物，其包含任何上述抗体，抗原，表位，多核苷酸，载体或细胞。 进一步描述了上述抗体，抗原，多核苷酸和载体在过继性免疫治疗中的用途，优选用于治疗或预防肝移植期间的HCV感染。